|
1100
|
Vaxchora
|
Cholera
|
Vibrio cholerae
|
Live attenuated
|
Emergent Travel Health Inc.
|
Approved
|
Oral
|
NA
|
NA
|
|
1101
|
Dukoral
|
Cholera
|
Vibrio cholerae
|
Inactivated
|
SBL Vaccines
|
Approved
|
Oral
|
31879125
|
NA
|
|
1102
|
Shanchol
|
Cholera
|
Vibrio cholerae
|
Inactivated
|
Shantha Biotechnics Limited
|
Approved
|
Oral
|
NA
|
NA
|
|
1103
|
Euvichol
|
Cholera
|
Vibrio cholerae
|
Inactivated
|
EuBiologics Co., Ltd.
|
Approved
|
Oral
|
31879125
|
NA
|
|
1104
|
Euvichol-plus
|
Cholera
|
Vibrio cholerae
|
Inactivated
|
EuBiologics Co., Ltd.
|
Approved
|
Oral
|
31879125
|
NA
|
|
1105
|
mORC-Vax
|
Cholera
|
Vibrio cholerae
|
Inactivated
|
Vabiotech, Hanoi
|
Approved
|
Oral
|
31879125
|
NA
|
|
1106
|
ORC-Vax
|
Cholera
|
Vibrio cholerae
|
Inactivated
|
Vabiotech, Hanoi
|
Approved
|
Oral
|
21498389
|
NA
|
|
1114
|
Vivotif
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Crucell Switzerland LTD
|
Approved
|
Oral
|
NA
|
NA
|
|
1115
|
Vivotif
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Emergent Travel Health Inc.
|
Approved
|
Oral
|
NA
|
NA
|
|
1186
|
CVD 1208S
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
University of Maryland, Baltimore
|
Clinical - Terminated
|
Oral
|
17938573
|
NCT00866476
|
|
1188
|
Sf2aWC
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Inactivated
|
PATH
|
Clinical - Withdrawn
|
Oral
|
26865592
|
NCT03038243
|
|
1194
|
WRSs2
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 2
|
Oral
|
30037478
|
NCT04242264
|
|
1195
|
WRSs2 and WRSs3
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 1
|
Oral
|
30037478
|
NCT01336699
|
|
1196
|
CVD 1208S-122
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
University of Maryland, Baltimore
|
Clinical - Phase 1
|
Oral
|
32257392
|
NCT04634513
|
|
1198
|
SC599
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
Institut Pasteur
|
Clinical - Phase 2
|
Oral
|
19135496
|
NCT00210288
|
|
1200
|
CVD1207
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Recombinant
|
NA
|
Clinical - Phase 1
|
Oral
|
10678904
|
NA
|
|
1202
|
WRSS1
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
U.S. Army Medical Research and Development Command
|
Clinical - Phase 1, Phase 2
|
Oral
|
30794051
|
NCT01080716
|
|
1213
|
CVD 1208S-122
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
University of Maryland, Baltimore
|
Clinical - Phase 1
|
Oral
|
32257392
|
NCT04634513
|
|
1214
|
VLA1701
|
E.coli Infections
|
Escherichia coli
|
NA
|
Valneva Austria GmbH
|
Clinical - Phase 2
|
Oral
|
NA
|
NCT03576183
|
|
1216
|
ACE527
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
TD Vaccines A/S
|
Clinical - Phase 1
|
Oral
|
NA
|
NCT00901654
|
|
1218
|
ACAM2007
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
NA
|
Clinical - Phase 1
|
Oral
|
17566016
|
NA
|
|
1219
|
ACAM2010
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
NA
|
Clinical - Phase 1
|
Oral
|
17566016
|
NA
|
|
1220
|
ACAM2017
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
NA
|
Clinical - Phase 1
|
Oral
|
17566016
|
NA
|
|
1221
|
ETEC expressing CFA/I and CFA/II
|
E.coli Infections
|
Escherichia coli
|
Inactivated
|
NA
|
Clinical
|
Oral
|
NA
|
NA
|
|
1232
|
CDVAX
|
Clostridium Difficile Infection
|
Clostridium difficile
|
Recombinant
|
Simon M. Cutting
|
Clinical - Terminated
|
Oral
|
NA
|
NCT02991417
|
|
1318
|
PXVX0200
|
Cholera
|
Vibrio cholerae
|
Live attenuated
|
Emergent BioSolutions
|
Clinical - Phase 3
|
Oral
|
21498389
|
NCT01895855
|
|
1319
|
Cholvax
|
Cholera
|
Vibrio cholerae
|
Inactivated
|
International Centre for Diarrhoeal Disease Research, Bangladesh
|
Clinical - Phase 2
|
Oral
|
31879125
|
NCT02742558
|
|
1320
|
Oral Cholera vaccine (in Vietnam)
|
Cholera
|
Vibrio cholerae
|
Inactivated
|
International Vaccine Institute
|
Clinical - Phase 2
|
Oral
|
NA
|
NCT00128011
|
|
1321
|
Choleragarde
|
Cholera
|
Vibrio cholerae
|
Live attenuated
|
International Vaccine Institute
|
Clinical - Phase 2
|
Oral
|
NA
|
NCT00741637
|
|
1322
|
VLA1701
|
Cholera
|
Vibrio cholerae
|
NA
|
Valneva Austria GmbH
|
Clinical - Phase 2
|
Oral
|
NA
|
NCT03576183
|
|
1323
|
HL-OCV
|
Cholera
|
Vibrio cholerae
|
Inactivated
|
International Centre for Diarrhoeal Disease Research
|
Clinical - Phase 1, Phase 2
|
Oral
|
NA
|
NCT02823899
|
|
1324
|
Peru-15-pCTB
|
Cholera
|
Vibrio cholerae
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 1
|
Oral
|
NA
|
NCT00654108
|
|
1329
|
Ty800
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
AVANT Immunotherapeutic
|
Clinical - Phase 2
|
Oral
|
NA
|
NCT00498654
|
|
1331
|
M01ZH09
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
University of Oxford
|
Clinical - Phase 2
|
Oral
|
NA
|
NCT01405521
|
|
1333
|
CVD 909
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 1
|
Oral
|
NA
|
NCT00326443
|
|
1334
|
CVD 908
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Centre for Vaccine Development, University of Maryland
|
Clinical - Phase 1
|
Oral
|
17582563
|
NA
|
|
1335
|
CVD 908-HTRA
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Evans Medical, Speke
|
Clinical - Phase 2
|
Oral
|
17582563
|
NA
|